# EARLY PHASE CLINICAL RESEARCH SUPPORT (Core-011)

> **NIH NIH P30** · UT SOUTHWESTERN MEDICAL CENTER · 2020 · $68,482

## Abstract

Harold C. Simmons Cancer Center 
Early Phase Clinical Research Support (EPCRS) 
Project Summary/Abstract 
One of the highest priorities of the Simmons Cancer Center is to effectively translate UT Southwestern (UTSW) 
scientific discoveries to the clinic. Translating these discoveries into clinical benefit often requires pre-clinical 
investigations to generate preliminary data needed to support clinical investigation. Funding this preclinical 
work has been difficult, since there are a number of costs associated with generation of preliminary data which 
are often unfunded by external sources. These include purchasing of imaging time; PK/PD studies; pre-and 
post-biopsies to assess biomarkers; determining a dosing regimen to be used in a clinical trial; development of 
novel imaging probes that provide functional and metabolic information. Early phase investigator-initiated 
translational research trials require significant regulatory, data management and research nursing resources 
that are not always available through traditional mechanisms in a timely fashion. The primary goals of the 
Cancer Center's Early Phase Clinical Research Support is to provide support to Cancer Center members for 
innovative pilot or Phase I studies, so as to capitalize on the science being carried out in the scientific 
programs. Only protocols which are investigator initiated, based on UTSW science, and likely to result in 
Phase II or III studies, will be funded. 
In 2013, we strengthened our Phase 1 program by recruiting an experienced Phase 1 Leader, Arthur Frankel, 
M.D., and provided dedicated space and personnel — a manager, research nurse and coordinators, data 
specialists, a dedicated senior regulatory associate, an administrative assistant and a protocol administrator to 
facilitate expansion of our phase 1 activities including investigator-initiated trials. This focus has led to an 
overall increase in accrual to all investigator-initiated early phase trials from 47 in 2009 to 231 in 2013, with an 
increase in accrual to investigator-initiated early phase studies supported by these personnel from 8 patients in 
2010 to 65 in 2013.

## Key facts

- **NIH application ID:** 10260736
- **Project number:** 3P30CA142543-10S3
- **Recipient organization:** UT SOUTHWESTERN MEDICAL CENTER
- **Principal Investigator:** Shaalan Beg
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $68,482
- **Award type:** 3
- **Project period:** 2010-08-03 → 2021-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10260736

## Citation

> US National Institutes of Health, RePORTER application 10260736, EARLY PHASE CLINICAL RESEARCH SUPPORT (Core-011) (3P30CA142543-10S3). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10260736. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*